Host Modulatory Effects of β-glucan on Localized Aggressive Periodontitis

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

combining the non-surgical therapy with a well-tolerated substance that can stimulate protective immune responses like B-glucan, might effectively mount resolution pathways contributing to resolving of the chronic lesion observed in aggressive forms of periodontal disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Al-Azhar University

Criteria

Inclusion Criteria:

• Except for periodontitis, patients were systemically healthy as evaluated by modified Cornell medical index.

• No more than two teeth other than first molars and incisors, with probing depth (PD) ≥ 5mm, bleeding on probing (BOP), and clinical attachment level (CAL) ≥ 5mm.

• Rapid rate of attachment loss and bone destruction.

• A radiographic examination revealing an evidence of moderate to severe vertical bone loss around permanent incisors and first molar teeth.

• Every patient should have at least 20 teeth excluding third (3rd) molars, and at least an extraction-indicated tooth for a dento-periodontal affection.

• Familial aggregation.

Exclusion Criteria:

• Previous subgingival scaling and root planing, allergy to β-glucan, smoking, former smoking, pregnancy, need of antibiotic coverage for routine dental therapy, antibiotic therapy in the previous 6 months and allergy to chlorhexidine.